Monday, June 5, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Antimicrobial Resistance

MIT Researchers Make Progress on Antibiotic Resistance Under DTRA-JSTO Research Program

by Global Biodefense Staff
October 12, 2021
MIT Researchers Make Progress on Antibiotic Resistance Under DTRA-JSTO Research Program

Colorized scanning electron micrograph of E. coli. Credit: NIAID

Researchers are making significant progress in antibiotic resistance under the Discovery of Medical Countermeasures Against New and Emerging threats (DOMANE) program of the Defense Threat Reduction Agency’s (DTRA) Chemical and Biological Technologies Department in its role as the Joint Science and Technology Office (JSTO) for Chemical and Biological Defense.

A research team at the Massachusetts Institute of Technology (MIT) discovered a new pathway used by E. coli bacteria for escaping antibiotic control.

When an antibiotic-resistant bacteria spreads unchecked, it poses a significant threat to military servicemembers and the public. Despite decades of research on fighting antibiotic resistance, new scientific understanding of the phenomenon remains a continued necessity. Discovering a mechanism for antibiotic resistance can present opportunities to design innovative therapeutic approaches to defeat bacterial infections and provide better protections for the servicemember and the nation.

Bacterial antibiotic-resistance mechanisms are complex but have traditionally been categorized into three broad groups:

  • Target modification occurs when the bacteria alter themselves to avoid interacting with the medicine, such as in mutations or sharing resistance genes
  • Drug inactivation occurs when the bacteria render the medicine ineffective
  • Drug transport failure occurs when the medicine is unable to reach its intended target to kill the bacteria

The researchers exposed actively growing E. coli to certain antibiotics that imposed selective pressures and enriched the survival of bacteria with mutations in the genes responsible for metabolism that had not been appreciated previously by scientists. By doing so, certain bacterial processes were minimized, such as respiration, which prevented the antibiotics from killing the bacteria and resulted in antibiotic resistance.

The research team discovered that several metabolism-specific mutations are abundant in the genomes of more than 3,500 clinical E. coli pathogens.

DTRA-JSTO’S DOMANE research expands the known processes for antibiotic resistance beyond the usual mechanisms. The discovery can be broadened beyond E.coli to bacterial biothreat agents, both endemic to certain geographic areas as well as those biologically engineered.

Story adapted from DTRA Chemical and Biological Technologies Department

Tags: AntimicrobialsDefense Threat Reduction AgencyE. coliEditor Pick

Related Posts

Vials of finished vaccines
Funding News

UK Biomanufacturing Fund to Bolster Supply Chain Resilience and Pandemic Preparedness

May 26, 2023
Dr. Sen Pei Discusses Challenges in Forecasting Antimicrobial Resistance
Antimicrobial Resistance

Dr. Sen Pei Discusses Challenges in Forecasting Antimicrobial Resistance

April 26, 2023
Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics
Industry News

Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics

April 20, 2023
Medical Countermeasures

Scientists Design Molecule to Slow SARS-Cov-2 Infection

March 29, 2023
Load More

Latest News

Vials of finished vaccines

UK Biomanufacturing Fund to Bolster Supply Chain Resilience and Pandemic Preparedness

May 26, 2023
Dr. Sen Pei Discusses Challenges in Forecasting Antimicrobial Resistance

Dr. Sen Pei Discusses Challenges in Forecasting Antimicrobial Resistance

April 26, 2023
Biodefense Headlines – 25 April 2023

Biodefense Headlines – 25 April 2023

April 25, 2023
Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics

Aptitude Awarded Up to $54M BARDA Funding for At-Home Diagnostics

April 20, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2023 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2023 Stemar Media Group LLC

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are okay with it.OkPrivacy policy